Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Whistleblower Management: Rogue FDA Reviewer Sets Tone to Start Avandia Committee; Forgotten By End

This article was originally published in RPM Report

Executive Summary

Avandia has been a contentious topic for FDA for six years. The latest advisory committee review highlights how far the agency has come in handling dissent – but also underscores the impact that a lone voice can have on delaying reviews, and prompting damaging headlines.


Related Content

Meta-Analyses After Avandia: FDA Hopes To Set Standards And Controls
Avandia Committee Gives Split Vote To Drug, But FDA Clear Winner
TMI from TIMI: Xarelto and the Trouble with Very Large Trials
The Inevitable Outcome: Diabetes Safety Model Expands to Weight Loss…and Beyond?
Lessons Learned: How Avandia is Changing the Way FDA Does Business
REMS 2.0: FDA Refining New Drug Safety Tools


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts